Dana-Farber Cancer Institute | Strategic Alliance Partners

July 06, 2023

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

July 04, 2023

Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.

July 04, 2023

Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.

July 03, 2023

The addition of first-line maintenance avelumab to best supportive care has sustained tolerability in patients with advanced urothelial carcinoma.

July 03, 2023

Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.

June 29, 2023

Guru P. Sonpavde, MD, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations.

June 29, 2023

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

June 29, 2023

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

June 28, 2023

Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.

June 27, 2023

Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.

June 27, 2023

Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.

June 26, 2023

Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shares the long-term findings from the pivotal CARTITUDE-1 trial, and highlights future directions for CAR T-cell therapy in this disease.

June 23, 2023

Nikhil C. Munshi, MD, discusses potential future directions for ciltacabtagene autoleucel and other CAR T-cell therapies in patients with multiple myeloma.

June 21, 2023

Pasi A. Jänne, MD, PhD, discusses findings from a first-in-human phase 1 trial investigating the EGFRxHER3 bispecific antibody-drug conjugate BL-B01D1 in patients with advanced non–small cell lung cancer and other advanced solid tumors.

June 20, 2023

Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.

June 20, 2023

Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.

June 19, 2023

Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.

June 19, 2023

Lakshmi Nayak, MD, discusses the treatment landscape for patients with primary central nervous system lymphoma and how tirabrutinib may serve as an option for those with relapsed/refractory disease.

June 14, 2023

Marios Giannakis, MD, PhD, discusses preliminary efficacy data from a phase 1 study of CGX1321 with or without pembrolizumab in advanced gastrointestinal tumors.

June 12, 2023

Toni Choueiri, MD, discusses the results of the phase 3 CONTACT-03 trial (NCT04338269) of atezolizumab and cabozantinib in patients with metastatic renal cell carcinoma.